.jpg)
When an FDA inspector raised questions about water streaming down some equipment in the fill-and-finish area at Dr. Reddy’s oncology plant in Duvvada, India, a quality control manager repeatedly waved it off as condensation. When the inspector pointed out it was flowing from a tube that someone had tried to fix with three zip ties and was a problem in a sterile area, the manager finally acquiesced and stopped the filling line.
Facing claims it induced doctors to prescribe a generic version of GlaxoSmithKline’s Coreg that violated its patents, Teva was hit with a hefty $235 million penalty in 2017. But a federal judge overruled that jury’s verdict last year—and now, one (US) federal appeals judge says she's “baffled" by the decision.
